Abstract
No validated biomarkers exist for minimal residual disease (MRD) detection in non-small cell lung cancer (NSCLC). Tumor DNA is continually shed into the circulation, where it can be accessed for analysis by next-generation sequencing (NGS). We aimed to design a NGS-based method for quantifying circulating tumor-derived DNA in NSCLC and other cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
